Antibody-drug conjugates (ADCs) are gaining traction in APAC, marked by significant investments and collaborations, particularly from Chinese companies, signaling strong potential in targeted cancer therapies.
GSK has secured an exclusive license for HS-20093, a B7-H3-targeted antibody-drug conjugate (ADC) from Hansoh Pharma, excluding mainland China, Hong Kong, Macau, and Taiwan.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.